Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Details Narrative)

v3.19.3
Stock-based Compensation (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jun. 20, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Number of options outstanding   1,293,630 334,400 1,293,630 334,400
Number of option purchase during period for vested       187,746  
Stock-based compensation expense   $ 269,129 $ 50,528 $ 394,164 $ 50,528
Employees [Member]          
Stock option contractual term 5 years        
Stock option exercise price $ 2.40        
Employees [Member] | Tranche One [Member] | Three Year Service Vesting [Member]          
Number of stock option granted 456,000        
Employees [Member] | Tranche Two [Member] | Phase 2a trial for PCS-499 Complete [Member]          
Number of stock option granted 90,646        
Employees [Member] | Tranche Two [Member] | Up-List From The OCTQB [Member]          
Number of stock option granted 271,938        
Employees [Member] | Tranche Two [Member] | In-license a new or additional drug [Member]          
Number of stock option granted 90,646        
Employees and Non-Employees [Member]          
Number of stock option granted         334,400